Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
May 02 2024 - 8:00AM
Science 37 Holdings, Inc. today disclosed the latest enrollment
figures resulting from its Metasite™ and Patient Recruitment
partnership with a leading biotech company whose asthma drug is
currently undergoing a Phase 3 clinical trial.
Leveraging its proprietary Metasite™ and Patient Recruitment
solutions, Science 37 contributed 28% of all randomized study
participants over a 15-month enrollment window. Science 37 averaged
44 patients enrolled per month, while each of the 55
brick-and-mortar sites supporting the trial enrolled an average of
two participants per month. Science 37 delivered an enrollment
velocity 22x greater than study sites in the trial and reduced the
study’s overall time-to-target enrollment.
“When a study sponsor entrusts us to fully accelerate its
clinical research, our role becomes twofold,” said Dr. Lianne
Marks, Medical Director and Primary Investigator at Science 37.
“The first is to improve upon the traditional patient recruitment
model using the built-in outreach, screening, and medical consent
advantages of our recruitment solution. The second is to further
enhance study conduct through our Metasite by expanding participant
access to the 90+ percent patient population that is unreachable in
brick-and-mortar research,” she added.
Science 37’s Patient Recruitment is available on a standalone
basis to clinical research sponsors and CROs looking to enhance
their patient enrollment efforts, or in combination with Science
37’s industry-leading flagship Virtual Site, the Metasite™, as part
of an accelerated research offering. For more information, please
visit www.science37.com.
About Science 37
Science 37’s mission is to accelerate clinical research by
enabling universal trial access for patients. Through our
solutions; the Metasite™ and Patient Recruitment, we accelerate
enrollment by expanding the reach of clinical trials to patients
beyond the traditional site and rigorously qualifying patients
prior to referring them to a traditional site. Our solutions are
powered by a proprietary technology stack with in-house medical and
operational experts that enhance quality through standardized
workflows and best-in-class study orchestration. To learn more,
visit www.science37.com, or email science37@science37.com.
To view studies that Science 37 is actively recruiting for,
please visit https://studies.science37.com/current-studies/.
Media InquiriesScience
37PR@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Aug 2023 to Aug 2024